Zacks Research Brokers Reduce Earnings Estimates for Humana

Humana Inc. (NYSE:HUM) – Investment analysts at Zacks Research cut their Q4 2024 earnings per share estimates for Humana in a research note issued on Wednesday, November 13th. Zacks Research analyst D. Chatterjee now anticipates that the insurance provider will earn ($2.31) per share for the quarter, down from their previous estimate of ($1.64). The consensus estimate for Humana’s current full-year earnings is $15.86 per share. Zacks Research also issued estimates for Humana’s Q3 2025 earnings at $3.72 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $16.65 EPS, Q1 2026 earnings at $6.27 EPS, Q2 2026 earnings at $5.51 EPS, Q3 2026 earnings at $2.90 EPS and FY2026 earnings at $14.96 EPS.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion.

A number of other research firms have also recently weighed in on HUM. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. KeyCorp initiated coverage on Humana in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and an average target price of $315.86.

Humana Price Performance

Humana stock opened at $271.35 on Monday. The firm has a fifty day moving average of $279.91 and a 200-day moving average of $331.59. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 52-week low of $213.31 and a 52-week high of $527.18. The firm has a market capitalization of $32.67 billion, a P/E ratio of 24.03, a PEG ratio of 2.17 and a beta of 0.52.

Hedge Funds Weigh In On Humana

Hedge funds have recently bought and sold shares of the business. Creative Financial Designs Inc. ADV lifted its stake in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. CarsonAllaria Wealth Management Ltd. raised its stake in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares in the last quarter. Atwood & Palmer Inc. acquired a new stake in Humana during the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in shares of Humana during the third quarter valued at $31,000. Finally, Your Advocates Ltd. LLP grew its stake in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.